Many Acorda Therapeutics, Inc.(ACOR) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Acorda Therapeutics Inc was Upgraded by JP Morgan to Overweight on Nov 30, 2016.
Company has reported several Insider transactions to the SEC, on Feb 13, 2017, Jane Wasman (President, Intl and GC) sold 54,536 shares at 22.30 per share price.On Feb 13, 2017, David Lawrence (Chief, Bus. Ops & PAO) sold 63,183 shares at 22.33 per share price.On Feb 13, 2017, Barry E Greene (director) sold 723 shares at 22.65 per share price.
Acorda Therapeutics Inc Last issued its quarterly earnings results on Feb 14, 2017. The company reported $0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.16. Analyst had a consensus of $0.21. The company had revenue of $134.00 million for the quarter, compared to analysts expectations of $139.67 million. The companys revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.28 EPS.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.86 by 7 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold.
Acorda Therapeutics, Inc. (NASDAQ:ACOR): 6 Analyst have given the stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) a near short term price target of $36.17. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $15.79. The higher price target estimate is at $60 while the lower price estimates are fixed at $21.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) witnessed a decline in the market cap on Tuesday as its shares dropped 2.25% or 0.55 points. After the session commenced at $23.65, the stock reached the higher end at $24.8 while it hit a low of $23.25. With the volume soaring to 1,499,639 shares, the last trade was called at $23.85. The company has a 52-week high of $37.36. The company has a market cap of $1,100 million and there are 46,114,306 shares in outstanding. The 52-week low of the share price is $16.4.
Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Companys lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.